RSV is a virus that can make people sick, especially older adults and babies. But even though RSV can be serious, people aren't as worried about it anymore. RSV is common but can be dangerous ...

Oct. 18, 2024 – Older people who aren’t sure about whether to get the vaccine for respiratory syncytial virus (RSV) now have a new set of data to help them make up their minds. A large study ...

So she was delighted when, last year, health authorities in the US and Europe approved the first vaccines for respiratory syncytial virus. RSV vaccines hold the potential to reduce the thousands ...

Rates of SUID per 100,000 live births rose by 10% from 2019 to 2021. A rise in rates of sudden unexpected infant deaths may have been linked to an off-season surge of respiratory syncytial virus ...

BUT HOW DO YOU KNOW IF IT’S THE FLU, RSV OR COVID? TO HELP YOU UNDERSTAND THE DIFFERENCE, THIS MORNING WE WELCOME DOCTOR VANESSA WALKER WITH SUTTER HEALTH. THANK YOU SO MUCH FOR BEING HERE.

One common respiratory illness, respiratory syncytial virus, or RSV, usually causes mild, cold-like symptoms, but it can be severe and even deadly for older people. “As we grow older ...

A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization. With U.S ...

Assembly of respiratory syncytial virus matrix protein lattice and its coordination with fusion glycoprotein trimers. Nature Communications , 2024; 15 (1) DOI: 10.1038/s41467-024-50162-x Cite This ...

The time for the cold-weather spread of COVID-19, influenza and respiratory syncytial virus (RSV) is quickly approaching. With it comes a new wave of illnesses that can result in school absences ...

Cold and flu season — otherwise known as mid-October — is upon us. But this year, several advancements in vaccines could help families keep viruses at bay. One of the new developments is a ...

Today, we talk about some RSV competition that’s brewing, how Alnylam’s CEO spoke about its plans with ATTR-CM, and more. Alnylam Pharmaceuticals is expanding the footprint of its RNA-based ...